Inactive Instrument

News Pulmatrix Inc Nasdaq

Equities

US74584P1030

Summary

Unlock all the news: Be the first to know and act before the market!

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	May. 30	AQ
MannKind Agrees to Cross License Deal With Pulmatrix	May. 29	MT
Pulmatrix Files Up to $95 Million Mixed Shelf	May. 17	MT
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine	May. 16	AQ
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine	May. 15	CI
Pulmatrix : Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - Form 8-K	May. 15	PU
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update	May. 13	AQ
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $5.9M	May. 10	MT
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer	Mar. 13	CI
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives	Jan. 09	AQ
Pulmatrix Explores Strategic Alternatives	Jan. 08	CI
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives	Jan. 08	DJ
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis	Jan. 08	CI
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 10	AQ
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M	Nov. 09	MT
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine	23-09-20	AQ
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	23-08-24	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Pulmatrix Inc Nasdaq

Equities

US74584P1030

Summary

Filters